Virtual Library

Start Your Search

Puyuan Xing



Author of

  • +

    EP1.12 - Small Cell Lung Cancer/NET (ID 202)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.12-11 - Effect of Treatment Mode on Prognosis of Resectable Limited-Stage Small Cell Lung Cancer (Now Available) (ID 1808)

      08:00 - 18:00  |  Author(s): Puyuan Xing

      • Abstract
      • Slides

      Background

      The optimal choice of post-operative treatment mode for resectable limited-stage small cell lung cancer (SCLC) is controversial in clinical practice. Different treatment modes may have different effects on prognosis of small cell lung cancer after resection.

      Method

      Data from a total of 122 patients with limited-stage SCLC undergoing operation were collected at our Cancer Hospital from 2012 to 2016. Clinical and pathological features, and treatment modes (including surgical methods, postoperative adjuvant radiotherapy and chemotherapy, prophylactic brain radiotherapy, etc.) were compared in small cell lung cancer after resection .The survival outcomes among different factors were analyzed by Kaplan-Meier method, and the survival differences among different factors were compared by log-rank method. Multivariate cox regression analysis was used to explore independent prognostic factors.

      Result

      The median follow-up time was 54.23 months. Among 122 patients, the 1-, 3- and 5-year overall survival (OS) rates were 95.08%, 75.14% and 63.79%, respectivly. The 1-, 3- and 5-year recurrence-free survival (RFS) rates were 80.99%, 66.62% and 61.86%, respectively. Recurrences were diagnosed in 56 (45%) patients, including 22 (39%) with brain metastasis, 15 (27%) with intrapulmonary recurrence, 7 (13%) with bone metastasis, 6 (11%) with hepatic metastasis, and 6 (11%) with other metastasis. Operation patterns affected OS. 116 patients received lobectomy and 6 patients received pneumonectomy. Median OS of these two groups were 68.37 and 35.37 months, respectively (p = 0.028). The T stage affected the postoperative OS. The median OS of T1、T2、T3 were 65.87, 71.29 and 29.92 months, respectively (p = 0.021). The disease-free survival (PFS) and OS of patients receiving adjuvant chemotherapy or combined with radiotherapy were longer than those receiving surgery only. The median PFS of adjuvant chemotherapy group, chemotherapy and radiotherapy combination group, and simple surgery group were 69.01,53.87 and 19.37 months, respectively (p=0.002). Accordingly, the median OS were 70.6, 65.56 and 30.8 months (p=0.002). Patients with postoperative prophylactic cranial irradiation (PCI) had a longer OS than those without PCI (62.28 vs. 78.84 months, p=0.028).

      Conclusion

      As for patients with resectable limited-stage SCLC,the 5-year survival rate of patients with surgery is higher than those without. Lobectomy is the optimal surgery mode, and adjuvant chemotherapy combined with prophylactic cranial irradiation after operation can significantly prolong the OS.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.